Unmanipulated haploidentical transplantation for adult patients with hematological malignancies.
作者信息
Ruggeri Annalisa, Santoro Nicole
机构信息
Department of Pediatric Haematology and Oncology, IRCCS, Ospedale Pediatrico Bambino Gesú, Rome, Italy.
Section of Hematology, Department of Medicine, University of Perugia, Centro Ricerche Emato-Oncologiche, Perugia, Italy.
出版信息
Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000247. eCollection 2019 Jun.
Abstract
摘要
相似文献
1
Unmanipulated haploidentical transplantation for adult patients with hematological malignancies.
Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000247. eCollection 2019 Jun.
2
Clinical impact of absolute lymphocyte count on day 30 after unmanipulated haploidentical blood and marrow transplantation for pediatric patients with hematological malignancies.
Am J Hematol. 2011 Feb;86(2):227-30. doi: 10.1002/ajh.21921.
3
Unmanipulated HLA-mismatched/haploidentical peripheral blood stem cell transplantation for high-risk hematologic malignancies.
Transfusion. 2012 Jun;52(6):1354-62. doi: 10.1111/j.1537-2995.2011.03478.x. Epub 2012 Jan 10.
4
Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched sibling transplantation.
Clin Microbiol Infect. 2013 Nov;19(11):1029-34. doi: 10.1111/1469-0691.12120. Epub 2013 Apr 8.
5
Haploidentical, G-CSF-primed, unmanipulated bone marrow transplantation for patients with high-risk hematological malignancies: an update.
Bone Marrow Transplant. 2015 Jun;50 Suppl 2:S24-30. doi: 10.1038/bmt.2015.91.
6
Innovative platforms for haploidentical stem cell transplantation: the role of unmanipulated donor graft.
J Cancer. 2011;2:339-40. doi: 10.7150/jca.2.339. Epub 2011 Jun 3.
7
Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies.
Blood. 2013 Jan 31;121(5):849-57. doi: 10.1182/blood-2012-08-453399. Epub 2012 Nov 19.
8
The impact of CD34+ cell dose on platelet engraftment in pediatric patients following unmanipulated haploidentical blood and marrow transplantation.
Pediatr Blood Cancer. 2009 Dec;53(6):1100-6. doi: 10.1002/pbc.22159.
9
Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status.
Biol Blood Marrow Transplant. 2009 May;15(5):632-8. doi: 10.1016/j.bbmt.2009.02.001.
10
Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
Ann Hematol. 2020 Aug;99(8):1883-1893. doi: 10.1007/s00277-020-04156-6. Epub 2020 Jun 22.
本文引用的文献
1
Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia 45 years of age and over.
Cancer. 2019 May 1;125(9):1499-1506. doi: 10.1002/cncr.31941. Epub 2019 Jan 8.
2
Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Haematologica. 2018 Aug;103(8):1317-1328. doi: 10.3324/haematol.2018.189258. Epub 2018 May 10.
3
Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT.
J Hematol Oncol. 2018 Apr 16;11(1):55. doi: 10.1186/s13045-018-0598-0.
4
Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report.
Bone Marrow Transplant. 2018 Sep;53(9):1139-1148. doi: 10.1038/s41409-018-0153-1. Epub 2018 Mar 14.
5
Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide.
Cancer. 2018 Apr 1;124(7):1428-1437. doi: 10.1002/cncr.31228. Epub 2018 Jan 23.
6
The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation.
Bone Marrow Transplant. 2018 May;53(5):521-534. doi: 10.1038/s41409-017-0062-8. Epub 2018 Jan 15.
7
Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation.
Blood. 2017 Oct 19;130(16):1857-1868. doi: 10.1182/blood-2017-05-785659. Epub 2017 Aug 23.
8
Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide.
J Clin Oncol. 2017 Sep 10;35(26):3002-3009. doi: 10.1200/JCO.2017.72.8428. Epub 2017 Jun 23.
9
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.
N Engl J Med. 2016 Jan 7;374(1):43-53. doi: 10.1056/NEJMoa1506002.
10
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.
J Clin Oncol. 2015 Oct 1;33(28):3152-61. doi: 10.1200/JCO.2014.60.4777. Epub 2015 Aug 10.
Zotero 插件